nejm tirzepatide 📢 New in NEJM: 💉 vs. Semaglutide 💉 for obesity (no diabetes) 🧪 72-week RCT highlights: ⚖️ Weight loss: −20.2% vs. −13.7% 📏 Waist ↓: 18.4 cm vs. 13.0 cm 🎯 More patients hit ≥25% loss… First head-to-head trial compares tirzepatide

Weight loss is the ultimate heart medication, and Tirzepatide is simply the tool that helps you get there safely

telehealth platforms provide safe, legal access at comparable or lower prices than international purchasing without the associated risks

Coverage can vary, with providers like United Healthcare, Cigna, Aetna, and Blue Cross Blue Shield offering support contingent on medical documentation and clinical need

While human data are still limited, this mitochondrial-derived peptide highlights a novel link between cellular energy sensing and systemic metabolic health, with potential relevance for insulin resistance and diabetes-related conditions